Glinil-M Tablet is a combination oral hypoglycemic agent containing Glibenclamide 5 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glibenclamide, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. The synergistic effect of these two agents provides effective glycemic control in patients inadequately controlled by diet, exercise, and monotherapy. Glinil-M is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and hypoglycemia, particularly due to the sulfonylurea component. Regular monitoring of blood glucose levels, renal function, and periodic assessment of liver function tests are recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. Glinil-M should be used cautiously in elderly patients and those with cardiovascular disease. Patient education on adherence and recognition of hypoglycemia symptoms is essential for optimal outcomes.